Literature DB >> 6160671

Human benign prostatic hyperplasia: a stromal disease? New perspectives by quantitative morphology.

H P Rohr, G Bartsch.   

Abstract

Stereology is of great value for better understanding the pathomorphogenesis of benign prostatic hyperplasia (BPH) and the hormonally controlled mechanism of abnormal overgrowth of the prostate gland, especially the stromal component. In human BPH a fourfold absolute increase of the stromal part and a nearly double increase of the glandular part is indicated. The relative and absolute increase of the stromal part is surprisingly constant in spite of variation of human BPH. Stromal overgrowth can be viewed as a central feature of BPH implicating altered mesenchymal-epithelial relationship. At the ultrastructural level in man and dog the volume density of the secretory droplets and lysosomes of the glandular cells is reduced. Stereology data confirm furthermore the activation of the smooth muscle cells suggesting an induction of stromal growth possibly induced by estrogen and/or androgen and an important role in glandular-stromal interactions.

Entities:  

Mesh:

Year:  1980        PMID: 6160671     DOI: 10.1016/0090-4295(80)90577-4

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  10 in total

Review 1.  Review of current and future approaches to the management of benign prostatic hyperplasia.

Authors:  J C Gingell
Journal:  Postgrad Med J       Date:  1992-09       Impact factor: 2.401

Review 2.  Targeting phenotypic heterogeneity in benign prostatic hyperplasia.

Authors:  Douglas W Strand; Daniel N Costa; Franto Francis; William A Ricke; Claus G Roehrborn
Journal:  Differentiation       Date:  2017-08-04       Impact factor: 3.880

3.  Genomic analysis of benign prostatic hyperplasia implicates cellular re-landscaping in disease pathogenesis.

Authors:  Lance W Middleton; Zhewei Shen; Sushama Varma; Anna S Pollack; Xue Gong; Shirley Zhu; Chunfang Zhu; Joseph W Foley; Sujay Vennam; Robert T Sweeney; Karen Tu; Jewison Biscocho; Okyaz Eminaga; Rosalie Nolley; Robert Tibshirani; James D Brooks; Robert B West; Jonathan R Pollack
Journal:  JCI Insight       Date:  2019-05-16

Review 4.  Terazosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in benign prostatic hyperplasia.

Authors:  M I Wilde; A Fitton; E M Sorkin
Journal:  Drugs Aging       Date:  1993 May-Jun       Impact factor: 3.923

5.  The accumulation of versican in the nodules of benign prostatic hyperplasia.

Authors:  Lawrence D True; Sarah Hawley; Thomas H Norwood; Kathleen R Braun; Stephen P Evanko; Christina K Chan; Richard C LeBaron; Thomas N Wight
Journal:  Prostate       Date:  2009-02-01       Impact factor: 4.104

6.  Immunohistochemical determination of age related proliferation rates in normal and benign hyperplastic human prostates.

Authors:  S Claus; M Wrenger; T Senge; H Schulze
Journal:  Urol Res       Date:  1993

7.  Targeting stromal androgen receptor suppresses prolactin-driven benign prostatic hyperplasia (BPH).

Authors:  Kuo-Pao Lai; Chiung-Kuei Huang; Lei-Ya Fang; Kouji Izumi; Chi-Wen Lo; Ronald Wood; Jon Kindblom; Shuyuan Yeh; Chawnshang Chang
Journal:  Mol Endocrinol       Date:  2013-07-26

Review 8.  Telomeres and telomerase in prostate cancer development and therapy.

Authors:  Mindy Kim Graham; Alan Meeker
Journal:  Nat Rev Urol       Date:  2017-07-04       Impact factor: 14.432

9.  A role for epithelial-mesenchymal transition in the etiology of benign prostatic hyperplasia.

Authors:  Paloma Alonso-Magdalena; Clemens Brössner; Angelika Reiner; Guojun Cheng; Nobuhiro Sugiyama; Margaret Warner; Jan-Ake Gustafsson
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-05       Impact factor: 11.205

Review 10.  Can Botulinum Toxin A Still Have a Role in Treatment of Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia Through Inhibition of Chronic Prostatic Inflammation?

Authors:  Bing-Juin Chiang; Hann-Chorng Kuo; Chun-Hou Liao
Journal:  Toxins (Basel)       Date:  2019-09-19       Impact factor: 4.546

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.